Cancer immunotherapy: synthetic and natural peptides in the balance

被引：27

作者：

Bellone, M

Iezzi, G

Imro, MA

Protti, MP

机构：

[1] Inst Sci H San Raffaele, Lab Tumor Immunol, I-20132 Milan, Italy

[2] Inst Sci H San Raffaele, Canc Immunotherapy & Gene Therapy Program, I-20132 Milan, Italy

来源：

IMMUNOLOGY TODAY | 1999年 / 20卷 / 10期

关键词：

D O I：

10.1016/S0167-5699(99)01503-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The identification of human tumor-associated antigens has opened new avenues for immune intervention in cancer. Clinical trials using synthetic peptides that match segments of known tumor-associated proteins are ongoing. Alternatively, naturally processed peptides, obtained by acid treatment of tumor cells can be used. Here, Matteo Bellone and colleagues discuss the advantages and disadvantages of synthetic versus natural tumor peptides in cancer immunotherapy.

引用

页码：457 / 462

页数：6

共 53 条

[21] Human tumor antigens recognized by T-cells [J].

Kawakami, Y ;

Rosenberg, SA .

IMMUNOLOGIC RESEARCH, 1997, 16 (04) :313-339

[22] EMPTY MHC CLASS-I MOLECULES COME OUT IN THE COLD [J].

LJUNGGREN, HG ;

STAM, NJ ;

OHLEN, C ;

NEEFJES, JJ ;

HOGLUND, P ;

HEEMELS, MT ;

BASTIN, J ;

SCHUMACHER, TNM ;

TOWNSEND, A ;

KARRE, K ;

PLOEGH, HL .

NATURE, 1990, 346 (6283) :476-480

[23] CTL INDUCTION BY A TUMOR-ASSOCIATED ANTIGEN OCTAPEPTIDE DERIVED FROM A MURINE LUNG-CARCINOMA [J].

MANDELBOIM, O ;

BERKE, G ;

FRIDKIN, M ;

FELDMAN, M ;

EISENSTEIN, M ;

EISENBACH, L .

NATURE, 1994, 369 (6475) :67-71

[24] Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11 [J].

Manici, S ;

Sturniolo, T ;

Imro, MA ;

Hammer, J ;

Sinigaglia, F ;

Noppen, C ;

Spagnoli, G ;

Mazzi, B ;

Bellone, M ;

Dellabona, P ;

Protti, MP .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :871-876

[25]

Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO

[26]

2-S

[27] Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [J].

Marchand, M ;

Weynants, P ;

Rankin, E ;

Arienti, F ;

Belli, F ;

Parmiani, G ;

Cascinelli, N ;

Bourlond, A ;

Vanwijck, R ;

Humblet, Y ;

Canon, JL ;

Laurent, C ;

Naeyaert, JM ;

Plagne, R ;

Deraemaeker, R ;

Knuth, A ;

Jager, E ;

Brasseur, F ;

Herman, J ;

Coulie, PG ;

Boon, T .

INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (06) :883-885

[28]

McKolanis J. R., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P466

[29] CAN ANTITUMOR IMMUNE-RESPONSES DISCRIMINATE BETWEEN SELF AND NONSELF [J].

MOUDGIL, KD ;

SERCARZ, EE .

IMMUNOLOGY TODAY, 1994, 15 (08) :353-355

[30] INDUCTION OF ANTIGEN-SPECIFIC CYTOLYTIC T-CELLS IN-SITU IN HUMAN-MELANOMA BY IMMUNIZATION WITH SYNTHETIC PEPTIDE-PULSED AUTOLOGOUS ANTIGEN-PRESENTING CELLS [J].

MUKHERJI, B ;

CHAKRABORTY, NG ;

YAMASAKI, S ;

OKINO, T ;

YAMASE, H ;

SPORN, JR ;

KURTZMAN, SK ;

ERGIN, MT ;

OZOLS, J ;

MEEHAN, J ;

MAURI, F .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :8078-8082

← 1 2 3 4 5 6 →